POST Online Media Lite Edition


Cougar Energy appoints new CEO and managing director

Staff writer |
Melbourne, Australia - July 24, 2012, Melbourne, Australia - Cougar Energy Limited announces that Rob Neill has been appointed chief executive officer and managing director of the company, effective August 6, 2012.

Neill will also be invited to join the Company’s Board of Directors on that date. Mr. Neill has had a successful track record in management positions within the resources sector and has built an extensive network of commercial contacts in the Asian region. In the UCG sector he held the role of Senior Commercial Manager at Linc Energy Limited where he worked across Linc’s divisions of UCG, Gas to Liquids, Drilling and Mergers & Acquisitions for more than two years.

Since leaving Linc Energy, Mr. Neill has been the CEO & Managing Director of NSP Asia Consulting, a boutique consulting firm based in Singapore advising investors and resources companies on mergers and acquisition opportunities in the coal and iron ore sectors in Asia and Australia.

His past experience includes roles as General Manager of Bucyrus Australia, a manufacturer and distributor of surface and underground mining equipment, and COO at Industrea Limited, a mining equipment manufacturer, distributor and provider of mining services.

Mr. Neill has also held executive management roles with Repco, Hagemeyer and Hitachi. His early working life included the completion of trade qualifications in a heavy engineering discipline within the surface and underground coal mining industry in Queensland’s Bowen Basin.


Boral appoints Zlatko Todorcevski as CEO and managing director
Thor Mining appoints Mark Potter as non-executive director
MC Mining Limited appoints Sebastiano Randazzo as non-executive director
Danakali Limited appoints Niels Wage as CEO
Centamin appoints Ibrahim Fawzy as independent non-executive director

What to read next

Len Walker steps down as Cougar Energy CEO
Andrew Matheson chairman of Cougar Energy
William F. Daly joins Halozyme Therapeutics